# Carthera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carthera

- Industry: Medical Devices & Equipment
- Headquarters: Lyon, France
- Website: www.carthera.eu
- Total disclosed funding: $56M
- Latest round: Series B (Dec 11, 2023)
- Investors on record: 8

## About

Based in France, Carthera is a healthcare platform dedicated to developing innovative ultrasound-based medical devices aimed at treating severe brain disorders such as glioblastoma and Alzheimer's Disease.Founded in 2010 and headquartered in Lyon, France, Carthera focuses on the development of ultrasound-based therapies for severe brain disorders. The company was established by Alexandre Carpentier, Delphine de La Ferrière-Carpentier, and Murielle Lemoine. Carthera has completed seven funding rounds, with its most recent round being a SERIES B in December 2023, raising EUR 4.5 million from investors including Bouscas S.A., SARL Heritiers Saint-Genys, Supernova Invest, and Unorthodox Ventures.Carthera specializes in developing innovative ultrasound-based medical devices designed to treat severe brain disorders, focusing primarily on glioblastoma, brain metastases, and neurodegenerative diseases such as Alzheimer's Disease. The cornerstone of their product offerings is the SonoCloud® device, which utilizes low-intensity pulsed ultrasound (LIPU) to temporarily increase the permeability of the blood-brain barrier (BBB). This unique approach allows for enhanced delivery of chemotherapy and other therapeutic agents directly to the brain, significantly improving the potential efficacy of these treatments. Released initially in clinical trials, SonoCloud® is designed to be used both before and after the injection of drugs, with investigations ongoing into its applications across various brain-related conditions. The technology is primarily aimed at hospitals and specialized treatment centers in key markets such as Europe and the United States, serving medical professionals and patients dealing with high unmet medical needs in neuro-oncology.In 2023, Carthera reported a revenue of EUR 25,421.10, with an EBITDA of EUR -7,526,222. The company generates revenue through partnerships and collaborations with pharmaceutical companies and healthcare institutions, focusing on the commercialization of its flagship device, SonoCloud®. Transactions typically involve agreements for the supply and integration of the SonoCloud® technology within existing treatment protocols for brain disorders, creating a direct channel for revenue as the device is integrated into clinical practices.In December 2023, Carthera raised EUR 4.5 million in SERIES B funding to support its growth initiatives. The company plans to further develop its SonoCloud® technology and explore new products aimed at enhancing treatment for severe brain conditions. Additionally, Carthera aims to expand its market presence in regions such as North America and Asia by 2025, utilizing the recent funding to bolster its clinical trials and establish partnerships that facilitate entry into these new markets.

## Funding rounds

- Series B, Dec 11, 2023, $4.8M — Supernova Invest, Unorthodox Ventures, SARL Heritiers Saint-Genys, Bouscas S.A.
- Series B, Jun 27, 2023, $41M — Turenne Groupe, Panakes Partners, Supernova Invest, European Innovation Council
- Series B, Dec 12, 2018, $10M — Turenne Groupe, Aglae Ventures, Panakes Partners, Supernova Invest

## Investors

- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B
- Aglae Ventures (https://capitalatlas.ai/funds/aglae-ventures) — Series B
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series B
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Unorthodox Ventures (https://capitalatlas.ai/funds/unorthodox-ventures) — Series B
- SARL Heritiers Saint-Genys — Series B
- Bouscas S.A. — Series B